KR20090005376A - 암 치료를 위한 18,21-디데스옥시막베신 유도체 - Google Patents

암 치료를 위한 18,21-디데스옥시막베신 유도체 Download PDF

Info

Publication number
KR20090005376A
KR20090005376A KR1020087027545A KR20087027545A KR20090005376A KR 20090005376 A KR20090005376 A KR 20090005376A KR 1020087027545 A KR1020087027545 A KR 1020087027545A KR 20087027545 A KR20087027545 A KR 20087027545A KR 20090005376 A KR20090005376 A KR 20090005376A
Authority
KR
South Korea
Prior art keywords
compound
strain
pharmaceutically acceptable
acceptable salt
didesoxymacbecin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020087027545A
Other languages
English (en)
Korean (ko)
Inventor
크리스틴 마르틴
밍 쟝
나이젤 코아테스
윌리암 보우스덴
스테벤 모쓰
사비네 가이쎄르
Original Assignee
바이오티카 테크놀로지 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0609132.6A external-priority patent/GB0609132D0/en
Priority claimed from GB0616637A external-priority patent/GB0616637D0/en
Priority claimed from GBGB0622341.6A external-priority patent/GB0622341D0/en
Application filed by 바이오티카 테크놀로지 리미티드 filed Critical 바이오티카 테크놀로지 리미티드
Publication of KR20090005376A publication Critical patent/KR20090005376A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
KR1020087027545A 2006-05-09 2007-05-09 암 치료를 위한 18,21-디데스옥시막베신 유도체 Withdrawn KR20090005376A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0609132.6 2006-05-09
GBGB0609132.6A GB0609132D0 (en) 2006-05-09 2006-05-09 Novel compounds and methods for their production
GB0616637A GB0616637D0 (en) 2006-08-22 2006-08-22 Novel compounds and methods for their production
GB0616637.5 2006-08-22
GBGB0622341.6A GB0622341D0 (en) 2006-11-09 2006-11-09 Novel compounds and methods for their preparation
GB0622341.6 2006-11-09

Publications (1)

Publication Number Publication Date
KR20090005376A true KR20090005376A (ko) 2009-01-13

Family

ID=38476939

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087027545A Withdrawn KR20090005376A (ko) 2006-05-09 2007-05-09 암 치료를 위한 18,21-디데스옥시막베신 유도체

Country Status (9)

Country Link
US (1) US20090253667A1 (cg-RX-API-DMAC7.html)
EP (1) EP1928837A2 (cg-RX-API-DMAC7.html)
JP (1) JP2009536181A (cg-RX-API-DMAC7.html)
KR (1) KR20090005376A (cg-RX-API-DMAC7.html)
AU (1) AU2007247121A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0711093A2 (cg-RX-API-DMAC7.html)
CA (1) CA2651558A1 (cg-RX-API-DMAC7.html)
MX (1) MX2008014278A (cg-RX-API-DMAC7.html)
WO (1) WO2007128829A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0718562A2 (pt) * 2006-11-09 2014-04-08 Biotica Tech Ltd Composto, processo para preparar e para gerar análogo de macbecina, análogo de macbecina, composição farmacêutica, uso do análogo de macbecina, e, cepa engenheirada.
EP2121957A4 (en) 2007-01-26 2010-11-10 Kosan Biosciences Inc MACROLACTAMES OBTAINED BY MODIFIED BIOSYNTHESIS
EP2129662A2 (en) * 2007-03-01 2009-12-09 Biotica Technology Limited C21-deoxy ansamycin derivatives as antitumor agents
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
CN101869138B (zh) * 2010-05-28 2012-05-30 江苏省农业科学院 一种微胶囊发酵剂储存保护液

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241754B2 (en) * 2003-06-13 2007-07-10 Kosan Biosciences, Inc. 2-Desmethyl ansamycin compounds
WO2007074347A1 (en) * 2005-12-24 2007-07-05 Biotica Technology Ltd. 21-deoxymacbecin analogues useful as antitumor agents

Also Published As

Publication number Publication date
CA2651558A1 (en) 2007-11-15
JP2009536181A (ja) 2009-10-08
AU2007247121A1 (en) 2007-11-15
US20090253667A1 (en) 2009-10-08
EP1928837A2 (en) 2008-06-11
WO2007128829A3 (en) 2008-01-03
BRPI0711093A2 (pt) 2011-08-23
MX2008014278A (es) 2008-11-26
WO2007128829A2 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
US7671190B2 (en) Recombinant polynucleotides encoding pro-geldanamycin producing polyketide synthases and accessory proteins, and uses thereof
CN101578268A (zh) 新的化合物及其生产方法
KR20080078853A (ko) 항암제로서 유용한 21-데옥시막베신 유사체
KR20090005377A (ko) 17-옥시막베신 유도체 및 이의 암 및/또는 b-세포 악성종양 치료 용도
KR20090078822A (ko) 암 치료를 위한 18, 21-디데스옥시막베신 유도체
CN111378008B (zh) 脂肽类化合物Totopotensamides及其制备方法和应用
EP0929681A1 (en) Rifamycin biosynthesis gene cluster
BRPI0711093A2 (pt) composto, composição farmacêutica, uso de um composto, métodos para o tratamento de um doença, e para a produção de um composto, cepa engenheirada, e uso de uma cepa engenheirada
KR20090075856A (ko) 신규한 화합물 및 이의 제조방법
CN101652348A (zh) C21-脱氧安莎霉素衍生物作为抗肿瘤剂
CN107540682B (zh) 曲张链丝菌素衍生物及其制备方法和应用
US20030175888A1 (en) Discrete acyltransferases associated with type I polyketide synthases and methods of use
CN101595095A (zh) 用于癌症治疗的18,21-双脱氧麦克菌素衍生物
CN101346354A (zh) 用作抗肿瘤剂的21-脱氧麦克菌素类似物
CN101027395A (zh) 用于制备复合聚酮化合物的生物合成基因簇
KR100549690B1 (ko) 에프알-008 폴리케타이드 합성에 관여하는 유전자
WO2007113270A1 (en) 15-o-desmethylmacbecin derivatives and their use in the treatment of cancer or b-cell malignancies
CN101736016A (zh) 萘霉素生物合成基因簇、包含其的载体及宿主
CN107541523B (zh) 曲张链丝菌素生物合成基因簇及其应用
KR20100089370A (ko) 슈도노카디아 오토트로피카의 신규한 폴리엔 생합성 유전자
EP2079700A1 (en) 18, 21-didesoxymacbecin derivatives for the treatment of cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20081110

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid